Non Small Cell Lung Cancer Clinical Trials in Buffalo, New York

10 studies are recruiting for non small cell lung cancer in Buffalo, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Buffalo, New York

   Locations

   328 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

2. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

   A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   38 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06343402 on ClinicalTrials.gov

3. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

   A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Cancer Center, Buffalo, New York

   Locations

   11 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT07027514 on ClinicalTrials.gov

4. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

5. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

   The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

   Stage

   Phase 2

   Ages

   18 to 95

   Site

   Research Site, Buffalo, New York

   Locations

   97 in total

   Run by

   AstraZeneca

   See if you can join NCT05061550 on ClinicalTrials.gov

6. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Cancer Center, Buffalo, New York

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

7. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

   This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   10 in total

   Run by

   Compass Therapeutics

   See if you can join NCT06150664 on ClinicalTrials.gov

8. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Cancer Institute, Buffalo, New York

   Locations

   20 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Buffalo, New York

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

10. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Roswell Park Cancer Institute, Buffalo, New York

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov